tiprankstipranks
Advertisement
Advertisement
BeOne Medicines upgraded to Buy from Hold at Jefferies
PremiumThe FlyBeOne Medicines upgraded to Buy from Hold at Jefferies
20d ago
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
Premium
Ratings
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
20d ago
BeOne Medicines Advances Minority-Focused Cancer Trial With Tislelizumab Combo
Premium
Company Announcements
BeOne Medicines Advances Minority-Focused Cancer Trial With Tislelizumab Combo
24d ago
BeOne Medicines price target raised to $451 from $436 at RBC Capital
PremiumThe FlyBeOne Medicines price target raised to $451 from $436 at RBC Capital
26d ago
AI Models Turn More Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
Premium
AI Analyst Ratings
AI Models Turn More Cautious on BeOne Medicines (ONC) as Valuation and Technicals Weigh
26d ago
AI Models Downgrade ONC as Valuation and Weak Technicals Offset Turnaround
Premium
AI Analyst Ratings
AI Models Downgrade ONC as Valuation and Weak Technicals Offset Turnaround
28d ago
BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors
PremiumCompany AnnouncementsBeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors
1M ago
BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers
Premium
Company Announcements
BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers
2M ago
BeOne Medicines announces presentation of Phase 3 data in CLL patients
Premium
The Fly
BeOne Medicines announces presentation of Phase 3 data in CLL patients
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100